Apolipoprotein E genotype does not predict decline in intelligence in healthy older adults
References (12)
- et al.
Early effect of ApoE-epsilon 4 allele on cognitive results in a group of highly performing subjects: the EVA study. Etude sur le Vieillissement Arteriel
Neurosci. Lett.
(1996) - et al.
Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E
Neurobiol. Aging
(2001) - et al.
Identifying and separating the effects of practice and of cognitive ageing during a large longitudinal study of elderly community residents
Neuropsychologia
(2001) - et al.
Apolipoprotein e4 allele and cognitive decline in elderly men
Br. Med. J.
(1994) - et al.
Apolipoprotein E and cognitive change in an elderly population
Ann. Neurol.
(1996) - et al.
Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia
Arch. Neurol.
(1998)
Cited by (41)
APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: A review
2018, CortexCitation Excerpt :The lower frequency of APOE-ε4 in the population, compared to APOE-ε3, has resulted in consistently smaller APOE-ε4 samples in most studies, unless specifically matched between groups (e.g., Caselli et al., 2001, 1999; Salvato et al., 2016; Zokaei et al., 2017). There are also relatively few investigations of the specific effect of APOE-ε2 on cognition, due to the low occurrence of the ε2 allele in the population (although see Bartrés-Faz et al., 1999; Batterham et al., 2013; Blair et al., 2005; Bloss et al., 2010; Bunce et al., 2014; Chey et al., 2000; Chiang, Raptentsetsang, & Jack, 2010; Greenwood et al., 2000; Helkala et al., 1995, 1996; Hofer et al., 2002; Marioni et al., 2016; Pendleton et al., 2002; Quintas et al., 2014; Salo et al., 2001; Staehelin et al., 1999; Ward et al., 2014; Wilson, Bienias, et al., 2002; Lancaster, Forster, et al., 2017). Table 1 also illustrates the variability in sample size across studies.
Posterior cortical atrophy
2012, The Lancet NeurologyCitation Excerpt :In some studies, significant differences between apolipoprotein E (APOE) genotypes have been noted in patients with PCA versus amnestic Alzheimer's disease.14,18,59 However, in other studies, no difference in APOE was recorded between PCA and typical Alzheimer's disease (table).17,21–23,60–64 Discrepancies between these studies could be attributable to differences in the inclusion criteria used to define PCA and typical Alzheimer's disease and age at onset.
Influence of apolipoprotein e ε4 on rates of cognitive and functional decline in mild cognitive impairment
2010, Alzheimer's and DementiaCitation Excerpt :Several longitudinal studies have reported that APOE ɛ4 is associated with cognitive decline among those without dementia [6,10–15], and have shown APOE ɛ4 to be predictive of the progression from aMCI to AD [8,16]. In contrast, a few studies have reported no association between APOE ɛ4 and cognitive decline [17–19] or found it not to be predictive, by itself, in the progression of aMCI to AD [7,20]. Our current longitudinal cohort, derived from a randomized placebo-controlled treatment trial, allows us to better establish and define APOE ɛ4-associated effects over time on specific cognitive and functional measures.
Challenges in phenotype definition in the whole-genome era: Multivariate models of memory and intelligence
2009, NeuroscienceCitation Excerpt :The apolipoprotein E gene and associated protein are involved in the breakdown of beta-amyloid deposits and has been implicated in Alzheimer's disease (Bertram and Tanzi, 2008). Three relatively large studies report no significant effect of the e-4 allele on IQ using different tests (Turic et al., 2001; Pendleton et al., 2002; Deary et al., 2004). In contrast, Ferguson and colleagues (2003), reported worse performance on WAIS-R-test for those with a copy of e-4, however, they studied 96 women all with type I diabetes.
Predicting memory decline in normal elderly: Genetics, MRI, and cognitive reserve
2007, Neurobiology of AgingCitation Excerpt :Some studies likewise have reported that AD patients with APOE-ɛ4 exhibited poorer performance on memory tasks [36,54,66], whereas others have not [4,52,53]. Many (reviewed by Nilsson et al. [67]) but not all [4,7,14,15,25,45,61,67,72,73,80] cross-sectional studies of non-demented middle-aged and elderly subjects with APOE-ɛ4 have reported poorer learning and memory [8,9,13,21,27,44,56,78,84,92] and other impairments in cognitive performance [6,32,44,82,101]. Longitudinal MRI studies of hippocampal changes in association with APOE-ɛ4 have been relatively sparse but have suggested that APOE-ɛ4 is associated with accelerated hippocampal-volume loss in healthy controls [15,63].